Please login to the form below

Not currently logged in

Sanofi-aventis appoints finance chief

Sanofi-aventis has appointed Jérôme Contamine as chief financial officer, effective March 16

Sanofi-aventis (S-A) has appointed Jérôme Contamine as chief financial officer, effective March 16. He takes the position left by the promotion of Laurence Debroux who took the new post of chief strategic officer in February 2009.

Contamine comes from outside the pharma sphere, but has extensive knowledge of international corporations, and, according to chief executive officer, Chris Viehbacher, he has the right experience to help S-A restructure to take it towards its goal of becoming a global healthcare leader.

"Jérôme will be deeply involved in the simplification of our operational structures to adapt our group to future challenges," said Viehbacher.

Contamine previously worked for Veolia Environment as senior executive vice president, deputy general manager and chief financial officer. He is a graduate of Ecole Polytechnique, a prestigious French engineering school, and ENSAE, the national statistics and economics engineering school, affiliated with the Ministry of Finance. He graduated from the Ecole Nationale d'Administration in the top 5 per cent. 

After four years at the "Cour des Comptes", as a senior state general auditor, he joined Elf Aquitaine in 1988, as advisor to the chief financial officer, and became group finance director and treasurer in 1991. He became the general manager of Elf Petroleum Norway in 1995. In 1999, he headed the taskforce for integration with Total, in charge of the reorganisation of the merged entity, TotalFinaElf, and in 2000, became vice president Europe and Central Asia, upstream division of Total. The same year, he joined Vivendi Environnement as chief financial officer, deputy general manager and member of the board.

11th March 2009


Featured jobs

Subscribe to our email news alerts


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...